Cancer Research
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global cancer research trends, drug development pipelines, and clinical trial advancements for strategic pharma investment.
Showing 1–12 of 25 articles
Quick answer
NovaPharmaNews Cancer Research hub for FDA covers 25 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets
ASCO 2026 Preview: Key Data and Trends in Cancer Research
Experimental pancreatic cancer drug offers new hope in major trial
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
STAT+: ASCO Preview: Key Insights for Pharma Leaders
Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference
Relay Therapeutics Q1 2026 Earnings: Zovegalisib PI3Kα Inhibitor Updates Expected May 5
Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
NCCN Adds Nuvation Bio's Taletrectinib (IBTROZI) to Cancer Treatment Guidelines for ROS1-Positive NSCLC with Brain Metastases
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.